Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Condition(s):Monoclonal Gammopathy; Smoldering Multiple MyelomaLast Updated:February 20, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Monoclonal Gammopathy; Smoldering Multiple MyelomaLast Updated:February 20, 2024Active, not recruiting
Condition(s):Waldenström MacroglobulinemiaLast Updated:November 23, 2022Completed
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 28, 2023Completed
Condition(s):Peripheral Neuropathy; Monoclonal Gammopathy of Undetermined SignificanceLast Updated:January 29, 2024Recruiting
Condition(s):Malignant Neoplasms of Male Genital Organs; Prostate CancerLast Updated:April 21, 2017Withdrawn
Condition(s):Refractory T-Cell Lymphoma; Relapsed T-Cell LymphomaLast Updated:August 2, 2022Active, not recruiting
Condition(s):Multiple MyelomaLast Updated:August 16, 2022Completed
Condition(s):MyelomaLast Updated:May 15, 2023Active, not recruiting
Condition(s):Multiple MyelomaLast Updated:April 21, 2022Withdrawn
Condition(s):Lymphoma, Primary EffusionLast Updated:March 27, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.